Tumor heterogeneity, within and between
tumors, may have severe implications for
tumor therapy, especially for targeted gene therapy, where single-targeted approaches often result in limited efficacy and
therapy resistance.
Polymer-formulated nonviral vectors provide a potent delivery platform for
cancer therapy. To improve applicability for future clinical use in a broad range of patients and
cancer types, a dual-targeting approach was performed. Synthetic LPEI-PEG2kDa-based
polymer backbones were coupled to two
tumor-specific
peptide ligands GE11 (EGFR-targeting) and cMBP (cMET-targeting). The dual-targeting approach was used to deliver the
theranostic sodium iodide symporter (NIS) gene to
hepatocellular cancer. NIS as auspicious
theranostic gene allows noninvasive imaging of functional NIS gene expression and effective anticancer radioiodide
therapy. Enhanced
tumor-specific transduction efficiency of dual-targeted polyplexes compared to single-targeted polyplexes was demonstrated in vitro using tumor cell lines with different EGFR and cMET expression and in vivo by 124I-PET-imaging. Therapeutic efficacy of the bispecific concept was mirrored by significantly reduced
tumor growth and perfusion, which was associated with prolonged animal survival. In conclusion, the dual-targeting approach highlights the benefits of a bifunctional strategy for a future clinical translation of the bioimaging-based NIS-mediated
radiotherapy allowing efficient targeting of heterogeneic
tumors with variable receptor expression levels.